Prof. Hermann Einsele at the Multiple Myeloma Hub

In a recent discussion on the Multiple Myeloma Hub, Prof. Hermann Einsele from partner UKW shared insights into the future role of anti-CD38 monoclonal antibodies (mAbs) in treating Multiple Myeloma. These therapies, including daratumumab and isatuximab, are increasingly being used in frontline treatment. Notably, the IMROZ Phase III trial showed that adding isatuximab to the standard VRd regimen significantly improved response rates and progression-free survival.

Beyond newly diagnosed cases, anti-CD38 mAbs are being studied in earlier disease stages, such as smoldering multiple myeloma, and in relapsed settings. Their combination with novel agents—including CELMoDs, bispecific antibodies, and CAR T-cell therapies—offers promising strategies to enhance outcomes and overcome resistance.

This evolving role highlights the potential of anti-CD38 antibodies to further reshape the treatment landscape of multiple myeloma.

Read more: https://multiplemyelomahub.com/medical-information/what-are-the-future-perspectives-for-anti-cd38-mabs-in-the-treatment-of-mm